8-K: Mangoceuticals Secures $100,000 Loan from CEO's Trust, Converts Preferred Stock to Common Shares, and Settles Lawsuit

Mangoceuticals, Inc. entered into a $100,000 loan agreement with The Tiger Cub Trust, converted preferred stock into common stock, and settled a lawsuit by issuing restricted common stock.

Summary

• Mangoceuticals, Inc. borrowed $100,000 from The Tiger Cub Trust, controlled by CEO Jacob D. Cohen, on May 2, 2025.
• The loan is evidenced by a Promissory Note with an 18% annual interest rate, compounded monthly.
• The Promissory Note matures on May 2, 2026, or earlier upon default or a Qualified Financing.
• Prepayment of the note requires a 'Make Whole Amount' premium.
• A 'Qualified Financing' triggers a mandatory prepayment of the note.
• The company converted 100 shares of Series B Convertible Preferred Stock into 73,333 shares of common stock on April 28, 2025, at a conversion price of $1.50 per share.
• On May 1, 2025, 300 shares of Series B Convertible Preferred Stock were converted into 220,000 shares of common stock at the same conversion price.
• Mangoceuticals settled a lawsuit with 1800 Diagonal Lending, LLC on May 5, 2025, by issuing 62,500 shares of restricted common stock.
• Following these transactions, the company has 11,034,023 shares of common stock outstanding.

Sentiment

Score: 5

Explanation: The news is mixed. Securing a loan and settling a lawsuit are positive, but the high interest rate and potential dilution are concerning.

Positives

• The $100,000 loan provides Mangoceuticals with additional capital.
• Settling the lawsuit with 1800 Diagonal Lending, LLC removes potential legal liabilities.

Negatives

• The 18% interest rate on the loan from The Tiger Cub Trust is relatively high.
• The 'Make Whole Amount' prepayment premium could make early repayment expensive.
• Issuing shares to settle the lawsuit dilutes existing shareholders' equity.

Risks

• Defaulting on the Promissory Note could lead to acceleration of the debt and an increased principal amount.
• The company's ability to raise capital through a 'Qualified Financing' could be impacted by market conditions.
• Further dilution of shareholders' equity could occur if more preferred stock is converted to common stock.

Future Outlook

The company may need to raise additional capital through a 'Qualified Financing' to repay the Promissory Note.

Industry Context

Small cap companies often rely on debt financing and equity conversions to fund operations and growth. Related party transactions, such as the loan from the CEO's trust, are common but require careful scrutiny.

Comparison to Industry Standards

• Interest rates on small business loans can vary widely, but 18% is on the higher end, suggesting Mangoceuticals may have limited access to cheaper capital.
• Conversion prices for preferred stock are typically set at a discount to the current market price to incentivize conversion.
• Settlements involving the issuance of stock are a common way to resolve legal disputes, but can dilute existing shareholders.
• Comparable companies that have used similar financing strategies include micro-cap pharmaceutical and biotech firms.

Legal Proceedings

• The company settled a lawsuit with 1800 Diagonal Lending, LLC by issuing 62,500 shares of restricted common stock.

Related Party Transactions

• Mangoceuticals borrowed $100,000 from The Tiger Cub Trust, which is controlled by the company's CEO, Jacob D. Cohen.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's financial stability is impacted by the new debt obligation.
• Employees may be affected by the company's ability to execute its business plan.

Next Steps

• Mangoceuticals will need to manage its debt obligations and potentially seek additional financing.
• The company will need to monitor its stock price and conversion rate of preferred stock.
• The company will need to execute its business plan to generate revenue and improve its financial position.

Key Dates

Keywords

Promissory Note, Convertible Preferred Stock, Settlement Agreement, Qualified Financing, Common Stock, Loan, Mangoceuticals